CING Stock Analysis: Buy, Sell, or Hold?
CING - Cingulate Inc. Common Stock
$5.38
-0.51 (-8.66%)
▼
5d:
+13.03%
30d:
+33.5%
90d:
-10.48%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 18, 2026
Get Alerted When CING Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CING shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CING shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CING is currently trading at $5.38, which is considered extended relative to its 30-day fair value range of $4.31 to $5.26.
Technical Outlook: Technically, CING is in a downtrend. Immediate support is located at $4.67, while resistance sits at $6.04. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: CING has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.00 (+327.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CING is in a downtrend. Immediate support is located at $4.67, while resistance sits at $6.04. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: CING has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.00 (+327.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.31 -
$5.26
Company Quality Score
65/100
(BUY)
Options IV Signal
17th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 17th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.7%)
- BULLISH: Trading 327.5% below Wall St target ($23.00)
Trading Range Analysis
30-Day Trading Range
$4.31 -
$5.26
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.66
(30.9%)
Support & Resistance Levels
Support Level
$4.67
Resistance Level
$6.05
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.27
Wall Street Target
$23.00
(+327.5%)
Share & Embed Analysis
Last updated: July 02, 2026 9:38 PM ET
Data refreshes hourly during market hours. Next update: 10:38 PM
Data refreshes hourly during market hours. Next update: 10:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CING showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jennifer L Callahan
BUY
4864 shares
2026-02-06
Matthew Brams
BUY
1946 shares
2026-02-06
Peter J Werth
BUY
19455 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |